New understanding of molecular changes that convert harmless cells surrounding ovarian cancer cells into cells that promote tumor growth and metastasis provides potential new therapeutic targets for this deadly disease, according to data published in the November 21, 2012 OnlineFirst issue of Cancer Discovery (Cancer Discov; 2(12); 1–9.) , a journal of the American…

The European Commission (EC) has approved bevacizumab (Avastin, Genentech/Roche)in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.

Bevacizumab is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to…

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase III clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin®, Genentech/Roche) effectively delayed the progression of…

The European Commission has approved bevacizumab (Avastin®, Roche) in combination with standard chemotherapy (carboplatin and paclitaxel) as a first-line treatment following surgery for women with advanced ovarian…

Depression, in addition to other barriers, may prevent Latina breast cancer survivors from undergoing preventive health screening for colorectal and ovarian cancer, according to data presented at the Fourth AACR Conference on The Science of Cancer Health Disparities, held in Washington DC, September 18-21, 2011.



“Depression can make people more inattentive to potential risks to their health and more likely to ignore recommendations to reduce their risk,”…

The European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on Nektar Therapeutics'application for orphan medicinal product status for the company's lead oncology candidate, NKTR-102, for the treatment of women with ovarian cancer.



Ovarian cancer is the fifth leading cause of cancer deaths among women, accounting for more deaths than any other cancer of the…

A Phase II clinical trial of SG2000 in ovarian cancer, being sponsored by the National Cancer Institute (NCI), is now actively recruiting patients for treatment for the treatmet of various forms of ovarian cancer

Ovarian cancer is the sixth most commonly diagnosed cancer in women and the eighth leading cause of cancer death among women worldwide, according to the American Cancer Society. Annually, an estimated 230,000 women are diagnosed with ovarian cancer around the world…

The first patients have been dosed in a new Phase I dose-escalation clinical study to evaluate NKTR-102, Nektar Therapeutics' lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.



NKTR-102, a novel topoisomerase I inhibitor-polymer conjugate compound, was invented by…

A Phase III Gynecologic Oncology Group (GOG) clinical trial finds that adding bevacizumab (Avastin®), a humanized anti-VEGF monoclonal antibody, to initial chemotherapy treatment – and then giving bevacizumab as maintenance therapy – significantly slows disease progression in women with advanced epithelial ovarian, primary peritoneal or fallopian tube cancer. The results of the study were presented during the 46^th annual meeting of the American Society of Clinical…